Table 1.
Baseline characteristics of participants of the Nolan Study with plasma p-tau181 assessment
| Total n = 289 | Nutritional blend n = 144 | Placebo n = 145 | p-value | |
|---|---|---|---|---|
| mean (SD)* | mean (SD)* | mean (SD)* | ||
| Sex (female) | 163 (56.4%) | 83 (57.6%) | 80 (55.2%) | 0.673a |
| Age (years) | 78.1 (4.7) | 78.3 (4.8) | 77.9 (4.7) | 0.435b |
| Age ranges | 0.769a | |||
| 70 to 74 years | 70 (24.2%) | 32 (22.2%) | 38 (26.2%) | |
| 75 to 79 years | 111 (38.4%) | 56 (38.9%) | 55 (37.9%) | |
| 80 to 84 years | 82 (28.4%) | 41 (28.5%) | 41 (28.3%) | |
| ≥85 years | 26 (9.0%) | 15 (10.4%) | 11 (7.6%) | |
| Education (n = 288) | 0.831a | |||
| ≤ 7 years | 24 (8.3%) | 13 (9.0%) | 11 (7.6%) | |
| 8 to 9 years | 45 (15.6%) | 21 (14.6%) | 24 (16.7%) | |
| ≥10 years | 219 (76.0%) | 110 (76.4%) | 109 (75.7%) | |
| Body mass index (kg/m2) | 26.2 (4.0) | 26.2 (3.8) | 26.3 (4.1) | 0.909b |
| <21 kg/m2 | 23 (8.0%) | 8 (5.6%) | 15 (10.3%) | 0.346a |
| 21 to 24.9 kg/m2 | 100 (34.6%) | 55 (38.2%) | 45 (31.0%) | |
| 25 to 29.9 kg/m2 | 115 (39.8%) | 57 (39.6%) | 58 (40.0%) | |
| ≥30 kg/m2 | 51 (17.6%) | 24 (16.7%) | 27 (18.6%) | |
| APOE ε4 status (n = 275) | 0.279a | |||
| ε4 carrier | 68 (24.7%) | 30 (21.9%) | 38 (27.5%) | |
| ε4 non-carrier | 207 (75.3%) | 107 (78.1%) | 100 (72.5%) | |
| Plasma p-tau181 (pg/mL) | 13.7 (5.8) | 14.1 (6.0) | 13.3 (5.6) | 0.262b |
| Plasma GFAP (pg/mL) (n = 283) | 182.7 (79.0) | 194.4 (87.6) | 171.0 (67.7) | 0.013c |
APOE, apolipoprotein E gene; GFAP, glial fibrillary acidic protein; p-tau181, phosphorylated tau at threonine 181; SD, standard deviation; *Except where indicated other. a Chi-Square test; b Equal variance two sample t-test, c Unequal variance two sample t-test.